Drugs / Thrombosomes
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02223117 | Sep 2014 → Jul 2016 | — | Cellphire Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03394755 | Mar 2018 → Aug 2019 | bone marrow failure syndrome, thrombocytopenia | Cellphire Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05771831 | Mar 2023 → Apr 2024 | aortic disorder | Jakob Stensballe, MD, PhD | Completed | No outcome recorded |
| Phase 2 | NCT04631211 | Mar 2021 → Jan 2022 | bone marrow failure syndrome, myelodysplastic syndrome, myeloproliferative neoplasm, thrombocytopenia | Cellphire Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| — | NCT04619108 Background | — | hemorrhagic disease | Cellphire Therapeutics, Inc. | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-09-26 | Cellphire Therapeutics, Inc. | Regulatory Cellphire Therapeutics Issued New Core Technology Patent covering the use of Stabilized Platelets for Drug Delivery cellphire.com ↗
today announced the United States Patent and Trademark Office (USPTO) issued a patent, entitled Platelets as Delivery Agents (US Patent 11,767,511, B2 ('511 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) for select drug delivery applications. |
| 2023-09-12 | Cellphire Therapeutics, Inc. | Regulatory Cellphire Therapeutics Issued New Core Technology Patent Covering Novel Manufacturing Processes and Product Attributes cellphire.com ↗ |
| 2020-05-18 | Cellphire Therapeutics, Inc. | Regulatory Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients cellphire.com ↗
Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia. |
| 2020-05-14 | Cellphire Therapeutics, Inc. | Regulatory Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome cellphire.com ↗
Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS). |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thrombosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03394755 ↗ |
| Modality | Other / unclassified | “Freeze-dried platelets” NCT02223117 ↗ |
| Route | Intravenous | “The intervention with TBX® is to be administered as an intravenous infusion” NCT05771831 ↗ |